FDA Expands Approval of Roche Cobas Test as CDx for EGFR Deletions, Mutations

Apr 19, 2018

NEW YORK (GenomeWeb) – Roche said today that the US Food and Drug Administration has granted premarket approval for expanded use of its Cobas EGFR Mutation Test v2 as a companion diagnostic test with AstraZeneca's Tagrisso (osimertinib) for non-small cell lung cancer patients.